Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126264 | 0.88 | MEN1 (0.41) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL16246036 | 0.86 | RAB9A (0.43) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL11466907 | 0.85 | DEGS1 (0.56) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL3306300 | 0.84 | PTK2 (0.59) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL17675503 | 0.84 | RAB9A (0.44) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL3202851 | 0.84 | RAB9A (0.44) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL465776 | 0.84 | RAB9A (0.47) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL3720037 | 0.84 | RAB9A (0.44) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| Hydrochloric Acid SCHEMBL8722614 | 0.82 | MEN1 (0.43) | RAB9AMAPTMEN1KMT2ADEGS1 | |
| SCHEMBL2664557 | 0.82 | HCAR3 (0.65) | RAB9AMAPTMEN1KMT2ADEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20230183182-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| CN-102227420-B | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2015-06-24 | — | — | CN | disclosed |
| CN-104394869-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-04 | — | — | CN | disclosed |
| CN-102378574-B | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2013-11-20 | — | — | CN | disclosed |
| CN-102378574-A | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2012-03-14 | — | — | CN | disclosed |
| CN-102227420-A | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-10-26 | — | — | CN | disclosed |
| EP-2344475-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2315763-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| CN-100522944-C | Carboxylic acid derivatives and salts thereof | EISAI CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| CN-1503774-A | Carboxylic acid derivatives and salts thereof | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| WO-2001002364-A1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | RAB9A 505/4885MAPT 3508/4885MEN1 83/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | RAB9A 1337/4885MAPT 2184/4885MEN1 455/4885 |
| US-20230183182-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | P2RX4, P2RX7, P2RX2 | RAB9A 3771/4885MAPT 394/4885MEN1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.